Biomarkers in the diagnosis of primary and recurrent breast cancer

Biomarkers in Medicine

Volumn 6, Issue 5, 2012, Pages 567-585

  Tang, Sarah S K ^a   Gui, Gerald P H ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

biomarkers; breast cancer; diagnosis; DNA methylation; proteomics

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AUTOANTIBODY; CAPECITABINE; CXCL9 CHEMOKINE; CYCLOPHOSPHAMIDE; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; LAPATINIB; LETROZOLE; MESSENGER RNA; METHOTREXATE; MICRORNA; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR MARKER;

BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INVASION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CPG ISLAND; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DNA METHYLATION; EARLY DIAGNOSIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FALSE POSITIVE RESULT; GENE EXPRESSION; HER2 GENE; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; NIPPLE ASPIRATION; OVERALL SURVIVAL; POSTMENOPAUSE; PREDICTIVE VALUE; PROTEOMICS; PROTO ONCOGENE; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

BREAST NEOPLASMS; CLINICAL LABORATORY TECHNIQUES; HUMANS; PROGNOSIS; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84867639216     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.75     Document Type: Review

References (95)

1. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25, 5287-5312 (2007). (Pubitemid 350232263)
2. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004). (Pubitemid 40051905)
3. Chang J, Ormerod M, Powles TJ et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 89, 2145-2152 (2000).
4. Viale G, Giobbie-Hurder A, Regan MM et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J. Clin. Oncol. 26, 5569-5575 (2008).
5. Deutscher SL, Dickerson M, Gui G et al. Carbohydrate antigens in nipple aspirate fuid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy BMC Cancer 10, 519 (2010).
6. Qin W, Gui G, Zhang K et al. Proteins and carbohydrates in nipple aspirate fuid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy. BMC Cancer 1(12), 52 (2012).
7. Pepe MS, Feng Z, Huang Y et al. Integrating the predictiveness of a marker with its performance as a classifer. Am. J. Epidemiol. 167, 362-368 (2008). (Pubitemid 351197592)
8. Armstrong K, Moye E, Williams S, Berlin JA, Reynolds EE. Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. Ann. Intern. Med. 146, 516-526 (2007). (Pubitemid 351650561)
9. Houssami N, Ciatto S, Irwig L, Simpson JM, MacAskill P. The comparative sensitivity of mammography and ultrasound in women with breast symptoms: an age-specifc analysis. Breast 11, 125-130 (2002). (Pubitemid 34679262)
10. Gail MH, Brinton LA, Byar DP et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl Cancer Inst. 81, 1879-1886 (1989). (Pubitemid 20026073)
11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the effcacy of adjuvant tamoxifen: patientlevel meta-analysis of randomised trials. Lancet 378, 771-784 (2011).
12. Ring A E, Smith IE, Ashley S, Fulford LG, Lakhani SR. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br. J. Cancer 91, 2012-2017 (2004). (Pubitemid 40128767)
13. Colleoni M, Viale G, Zahrieh D et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin. Cancer Res. 10, 6622-6628 (2004). (Pubitemid 39346559)
14. The Breast International Group (BIG) 1-98 Collaborative Group; Thürlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353, 2747-2757 (2005). (Pubitemid 43016814)
15. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005).
16. Henson DE, Ries L, Freedman LS, Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22, 616 cases of breast cancer: the basis for a prognostic index. Cancer 68, 2142-2149 (1991).
17. Mook S, Schmidt MK, Rutgers EJ et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol. 10, 1070-1076 (2009).
18. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res. Treat. 22, 207-219 (1992).
19. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classifcation and prognosis based on gene expression profles from a population-based study. Proc. Natl Acad. Sci. USA 100, 10393-10398 (2003). (Pubitemid 37071889)
20. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005). (Pubitemid 41464706)
21. Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005). (Pubitemid 41464705)
22. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006). (Pubitemid 46021510)
23. Wang Y, Yin Q, Zhang J et al. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. Breast Cancer Res. Treat. 130, 489-498 (2011).
24. Voduc KD, Cheang MCU, Tyldesley S et al. Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 28, 1684-1691 (2010).
25. Trihia H, Murray S, Price K et al. Ki-67 expression in breastcarcinoma: its association with grading systems, clinical parameters, and other prognostic factors - a surrogate marker? Cancer 97, 1321-1331 (2003). (Pubitemid 36237320)
26. Haerslez T, Jacobsen GK, Zedeler K. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res. Treat. 37, 101-113 (1996). (Pubitemid 26030089)
27. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J. Clin. Oncol. 23, 7212-7220 (2005).
28. de Azambuja E, Cardoso F, de Castro G Jr et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients. Br. J. Cancer 96, 1504-1513 (2007). (Pubitemid 46762956)
29. Stuart-Harris R, Caldas C, Pinder SE, Pharaoh P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32, 825 patients. Breast 17, 323-334 (2008).
30. Cheang MCU, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl Cancer Int. 101, 736-750 (2009).
31. Jones RL, Salter J, A'Hern R et al. The prognostic signifcance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res. Treat. 116, 53-68 (2009).
32. Dowsett M, Ebbs SR, Dixon JM et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: infuence of hormonal status and HER-2 in breast cancer - a study from the IMPACT trialists. J. Clin. Oncol. 23, 2477-2492 (2005). (Pubitemid 47050838)
33. van 't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profling predicts clinical outcome of breast cancer. Nature 415(6871), 530-536 (2002). (Pubitemid 34130608)
34. Cardoso F, Piccart-Gebhart M, van 't Veer L, Rutgers E. The MINDACT trial: the frst prospective clinical validation of a genomic tool. Mol. Oncol. 1, 246-251 (2007). (Pubitemid 350181650)
35. Cardoso F, van 't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profle: the MINDACT trial. J. Clin. Oncol. 26, 729-735 (2008). (Pubitemid 351264385)
36. Wang Y, Klijn JG, Zhang Y et al. Geneexpression profles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679 (2005). (Pubitemid 40260888)
37. Chang HY, Nuyten DS, Sneddon JB et al. Robustness, scalability and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl Acad. Sci. USA 102, 3738-3743 (2005). (Pubitemid 40354681)
38. Finak G, Bertos N, Pepin F et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518-527 (2008). (Pubitemid 351655218)
39. Farmer P, Bonnefoi H, Anderle P et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 15, 68-74 (2009).
40. Chaiwun B, Thorner P. Fine needle aspiration for evaluation of breast masses. Curr. Opin. Obstet. Gynecol. 19, 48-55 (2007). (Pubitemid 46095873)
41. Bondeson L, Lindholm K. Prediction of invasiveness by aspiration cytology applied to non-palpable breast carcinoma and tested in 300 cases. Diagn. Cytopathol. 17, 315-312 (1997).
42. King BL, Love SM. The intraductal approach to the breast: raison d'etre. Breast Cancer Res. 8, 206 (2006).
43. Khan SA, Wiley EL, Rodriguez N et al. Ductal lavage fndings in women with known breast cancer undergoing mastectomy. J. Natl Cancer Inst. 96, 1510-1517 (2004). (Pubitemid 39445532)
44. Noble J, Dua S, Locke I et al. Proteomic analysis of nipple aspirate fuid throughout the menstrual cycle in healthy pre-menopausal women. Breast Cancer Res. Treat. 104, 191-196 (2007). (Pubitemid 47084223)
45. Peng J, Elias JE, Thoreen CC, Licklider LJ, Gygi SP. Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. J. Proteome Res. 2, 43-50 (2003). (Pubitemid 36207189)
46. Washburn MP, Wolters D, Yates Jr. Large-scale analysis of the yeast proteome by multidimensional protein identifcation technology. Nat. Biotechnol. 19, 242-247 (2001). (Pubitemid 32220565)
47. Bernstein JL, Godbold JH, Raptis G et al. Identifcation of mammaglobin as a novel serum marker for breast cancer. Clin. Cancer Res. 11, 6528-6535 (2005). (Pubitemid 41338991)
48. Ruiz-Garcia E, Scott V, Machavoine C et al. Gene expression profling identifes fbronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening. Br. J. Cancer 102, 462-468 (2010).
49. Bronger H, Kraeft S, Schwarz-Boeger U et al. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. Breast Cancer Res. 14, R30 (2012).
50. Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28, 105-113 (2010).
51. Specht K, Harbeck N, Smida J et al. Expression profling identifes genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy. Breast Cancer Res. Treat. 118, 45-56 (2009).
52. Atahan K, Küpeli H, Gür S et al. The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer. Int. J. Med. Sci. 8, 148-155 (2011).
53. Opstal-van Winden AMJ, Krop EJM, Kåredal MH et al. Searching for early breast cancer biomarkers by serum protein profling of pre-diagnostic serum; a nested case-control study. BMC Cancer 11, 381 (2011).
54. Li CI. Discovery and validation of breast cancer early detection biomarkers in preclinical samples. Horm. Cancer 2, 125-131 (2011).
55. Noble JL, Dua RS, Coulton GR, Isacke CM, Gui GPH. A comparative proteinomic analysis of nipple aspiration fuid from healthy women and women with breast cancer. Eur. J. Cancer 43, 2315-2320 (2007). (Pubitemid 47625974)
56. Pawlik TM, Fritsche H, Coombes KR et al. Signifcant differences in nipple aspirate fuid protein expression between healthy women and those with breast cancer demonstrated by time-of-fight mass spectrometry. Breast Cancer Res. Treat. 89, 149-157 (2005). (Pubitemid 40253557)
57. Sauter ER, Shan S, Hewett JE, Speckman P, Du Bois GC. Proteomic analysis of nipple aspirate fuid using SELDI-TOF-MS. Int. J. Cancer. 114(5), 791-796 (2005). (Pubitemid 40344440)
58. He J, Gornbein J, Shen J et al. Detection of breast cancer biomarkers in nipple aspirate fuid by SELDI-TOF and their identifcation by combined liquid chromatography-tandem mass spectrometry. Int. J. Oncol. 30, 145-154 (2007).
59. Alexander H, Stegner AL, Wagner-Mann C et al. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fuid. Clin. Cancer Res. 10, 7500-7510 (2004). (Pubitemid 39557511)
60. Sauter ER, Wagner-Mann C, Ehya H, Klein-Szanto A. Biologic markers of breast cancer in nipple aspirate fuid and nipple discharge are associated with clinical fndings. Cancer Detect. Prev. 31, 50-58 (2007). (Pubitemid 46367450)
61. Sanders ME, Dias EC, Xu BJ et al. Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS. J. Proteome Res. 7, 1500-1507 (2008).
62. Trede D, Schiffer S, Becker M et al. Exploring the three dimensional matrixassisted laser desorption/ionization imaging mass spectrometry data: three dimensional spatial segmentation of mouse kidney. Anal. Chem. 84, 6079-6087 (2012).
63. Kouzarides T. Chromatin modifcations and their function. Cell 128, 693-705 (2007).
64. Fackler MJ, McVeigh M, Mehrotra J et al. quantitative multiplex methylation-specifc PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res. 64, 4442-4452 (2004). (Pubitemid 38856915)
65. Fackler MJ, Malone K, Zhang Z et al. Quantitative multiplex methylation-specifc PCR analysis doubles detection of tumor cells in breast ductal fuid. Clin. Cancer Res. 12, 3306-3310 (2006).
66. Weisenberger DJ, Trinh BN, Campan M et al. DNA methylation analysis by digital bisulfte genomic sequencing and digital MethyLight. Nucleic Acids Res. 36, 4689-4698 (2008).
67. Lee JS, Fackler MJ, Teo WW et al. Quantitative promoter hypermethylation profles of ductal carcinoma in situ in North American and Korean women: potential applications for diagnosis. Cancer Biol. Ther. 7, 1398-1406 (2008).
68. Euhus DM, Bu D, Milchgrub S et al. DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 17, 1051-1059 (2008).
69. Euhus DM, Bu D, Ashfaq R et al. Atypia and DNA methylation in nipple duct lavage in relation to predicted breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 16, 1812-1821 (2007). (Pubitemid 47450511)
70. Lewis CM, Cler LR, Bu DW et al. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin. Cancer Res. 11, 166-172 (2005). (Pubitemid 40081117)
71. Subramaniam MM, Chan JY, Soong R et al. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res. Treat. 113, 113-121 (2008).
72. Jiang Y, Tong D, Lou G, Zhang Y, Geng J. Expression of RUNX3 gene, methylation status and clinicopathological signifcance in breast cancer and breast cancer cell lines. Pathobiology 75, 244-251 (2008). (Pubitemid 351918429)
73. Pu RT, Laitala LE, Alli PM, Fackler MJ, Sukumar S, Clark DP. Methylation profling of benign and malignant breast lesions and its application to cytopathology. Mod. Pathol. 16, 1095-1101 (2003). (Pubitemid 37414203)
74. Fackler MJ, McVeigh M, Evron E et al. DNA methylation of RASSF1A, HIN-1, RAR-β, cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int. J. Cancer 107, 970-975 (2003). (Pubitemid 37429839)
75. Antill YC, Mitchell G, Johnson SA et al. Gene methylation in breast ductal fuid from BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol. Biomarkers Prev. 19, 265-274 (2010).
76. Zhang W, Yang YC, Zhang BN et al. Biomarker analysis on breast ductal lavage cells in women with and without breast cancer. Int. J. Cancer 119, 359-364 (2006).
77. Brennan K, Garcia-Closas M, Orr N et al. Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res. 72, 2304-2313 (2012).
78. Radpour R, Barekati Z, Kohler C et al. Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One 6, e16080 (2011).
79. Cho YH, Yazici H, Wu HC et al. Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients. Anticancer Res. 30, 2489-2496 (2010).
80. Maier S, Nimmrich I, Koenig T et al.; European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients [Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group]. Eur. J. Cancer 43, 1679-1686 (2007). (Pubitemid 47042374)
81. Lehmann U, Hasemeier B, Christgen M et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J. Pathol. 214, 17-24 (2008).
82. Wojdacz TK, Thestrup BB, Cold S, Overgaard J, Hansen LL. No difference was identifed in the frequency of locus specifc methylation in the peripheral blood DNA of women diagnosed with breast cancer and age-matched controls. Future Oncol. 7, 1451-1455 (2011).
83. Brooks JD, Cairns P, Shore RE et al. DNA methylation in pre-diagnostic serum samples of breast cancer cases: results of a nested case-control study. Cancer Epidemiol. 34, 717-723 (2010).
84. Van der Auwera I, Bovie C, Svensson C et al. Quantitative assessment of DNA hypermethylation in the infammatory and non-infammatory breast cancer phenotypes. Cancer Biol. Ther. 8, 2250-2257 (2009).
85. Chan DW, Beveridge RA, Muss H et al. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J. Clin. Oncol. 15, 2322-2328 (1997). (Pubitemid 27251134)
86. Kerlikowske K, Molinaro AM, Gauthier ML et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J. Natl Cancer Inst. 102, 627-637 (2010).
87. Kerlikowske K, Molinaro A, Cha I et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J. Natl Cancer Inst. 95, 1692-1702 (2003). (Pubitemid 37509078)
88. Solin LJ, Kurtz J, Fourquet A et al. Fifteen-year results of breast-conserving surgery and defnitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J. Clin. Oncol. 14, 754-763 (1996). (Pubitemid 26085518)
89. Asiago VM, Alvarado LZ, Shanaiah N et al. Early detection of recurrent breast cancer using metabolite profling. Cancer Res. 70, 8309-8318 (2010).
90. Zhou X, Marian C, Makambi KH et al. MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status. PLoS One 7(6), e39011 (2012).
91. Storr SJ, Chakrabarti J, Barnes A, Murray A, Chapman CJ, Robertson JF. Use of autoantibodies in breast cancer screening and diagnosis. Expert Rev. Anticancer Ther. 6, 1215-1223 (2006). (Pubitemid 44304689)
92. Chapman C, Murray A, Chakrabarti J et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann. Oncol. 18, 868-873 (2007). (Pubitemid 47054083)
93. Boyle P, Chapman CJ, Holdenrieder S et al. Clinical validation of an autoantibody test for lung cancer. Ann. Oncol. 22, 383-389 (2011).
94. McShane LM, Douglas GA, Sauerbrei W et al. REporting recommendations for tumorMARKer prognostic studies (REMARK). Breast Cancer Res. Treat. 100, 229-235 (2006). (Pubitemid 44631925)
95. Simon RM, Paik SM, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl Cancer Inst. 101, 1446-1452 (2009).